2,3-二羟基-6-氯喹喔啉 | 6639-79-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2,3-二羟基-6-氯喹喔啉
• 中文别名: 6-氯-2,3-二氧代-1,2,3,4-四氢喹喔啉；6-氯-2,3(1H,4H)-喹喔啉二酮
• 英文名称: 6-chloroquinoxaline-2,3(1H,4H)-dione
• 英文别名: 6-chloro-1,2,3,4-tetrahydroquinoxaline-2,3-dione；6-chloro-1,4-dihydroquinoxaline-2,3-dione；NSC 48940；6-Chloroquinoxaline-2,3-diol
• CAS: 6639-79-8
• 化学式: C₈H₅ClN₂O₂
• 分子量: 196.593
• InChiKey: RNOLFZACEWWIHP-UHFFFAOYSA-N

物化性质

• 熔点：
  >350 °C(Solv: ethanol (64-17-5))
• 密度：
  1.475±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 储存条件：
  2-8°C

SDS

Name:	6-Chloro-1 2 3 4-tetrahydroquinoxaline-2 3-dione 97% Material Safety Data Sheet
Synonym:
CAS:	6639-79-8

Section 1 - Chemical Product MSDS Name:6-Chloro-1 2 3 4-tetrahydroquinoxaline-2 3-dione 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6639-79-8	6-Chloro-1,2,3,4-tetrahydroquinoxaline	97%	229-647-9

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6639-79-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 250 deg C (dec.)
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H5ClN2O2
Molecular Weight: 196.59

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6639-79-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
6-Chloro-1,2,3,4-tetrahydroquinoxaline-2,3-dione - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 6639-79-8: No information available.
Canada
CAS# 6639-79-8 is listed on Canada's NDSL List.
CAS# 6639-79-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6639-79-8 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,3-二羟基-6-氯喹喔啉 在 盐酸 、 sodium 、 一水合肼 、 溶剂黄146 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 84.5h， 生成 7-chloro-4-(diethylamino)<1,2,3>triazolo<4,3-a>quinoxaline
  参考文献：
  名称：

  4-氨基[1,2,4]三唑并[4,3-a]喹喔啉。一类新型的有效腺苷受体拮抗剂和潜在的快速发作抗抑郁药。

  摘要：

  制备了一系列的4-氨基[1,2,4]三唑并[4,3-a]喹喔啉。此类化合物中的许多化合物在急性给药后可降低大鼠Porsolt行为绝望模型的固定性，因此可能具有作为新型且速效抗抑郁药的治疗潜力。该测试中的最佳活性与1位上的氢，CF3或小烷基，与4位上的小烷基取代的NH2，NH-乙酰基或胺以及氢或8个卤素取代基有关在芳香环上。此外，许多这些4-氨基[1,2,4]三唑并[4,3-a]喹喔啉与腺苷A1和A2受体狂热结合，在某些情况下非常选择性地结合。这些化合物的A1亲和力是通过抑制大鼠大脑皮层膜中tri化的CHA（N6-环己基腺苷）结合而测定的，A2亲和性是通过抑制tri化的NECA（5'-（N-乙基氨基甲酰基）腺苷）与大鼠纹状体匀浆中的结合来测定的。存在冷的N6-环戊基腺苷。结构-活性关系（SAR）研究表明，最佳的A1亲和力与1位的乙基，CF3或C2F5、4位的NH-iPr或NH-环烷基以及8-

  DOI：

  10.1021/jm00170a031
• 作为产物：
  描述：

  6-氯喹喔啉 在 水 、 [双(三氟乙酰氧基)碘]苯 作用下， 以 乙腈 为溶剂， 反应 24.0h， 以82%的产率得到2,3-二羟基-6-氯喹喔啉
  参考文献：
  名称：

  使用超价λ为氧化喹喔啉，Tetraazaphenanthrene和六氮杂部分的直接方法3种-Iodinane化合物

  摘要：

  各种含贫电子的喹喔啉核心化合物，例如喹喔啉，1,4,5,8-四氮杂菲和1,4,5,8,9,12-六氮杂苯并菲的有效氧化反应，使用[双（三氟乙酰氧基）碘]苯的报道。使用乙腈/水溶剂混合物，可以在室温下将这些化合物以高收率或高收率转化为相应的喹喔啉二酮。这种空前的反应应能够合成可用于多个化学领域的多种化合物。

  DOI：

  10.1021/jo401872e

文献信息

• A new facile, efficient synthesis and structure peculiarity of quinoxaline derivatives with two benzimidazole fragments
  作者：Vakhid A. Mamedov、Nataliya A. Zhukova、Victor V. Syakaev、Aidar T. Gubaidullin、Tat'yana N. Beschastnova、Dil'bar I. Adgamova、Aida I. Samigullina、Shamil K. Latypov

  DOI：10.1016/j.tet.2012.10.045

  日期：2013.1

  A highly efficient and versatile method for the synthesis of quinoxaline derivatives with two benzimidazole fragments have been developed on the basis of the ring contraction of 3-(benzimidazo-2-yl)quinoxalin-2(1H)-one with 1,2-diaminobenzene and its various types of substituted and condensed derivatives. Owing to the inter- and intramolecular processes, involving self association, proton exchange

  基于3-（苯并咪唑-2-基）喹喔啉-2（1 H）-与1,2-的环收缩，已开发出一种高效且通用的具有两个苯并咪唑片段的喹喔啉衍生物的合成方法。二氨基苯及其各种类型的取代和稠合衍生物。由于分子间和分子内过程，涉及桥联和相邻碳原子的大多数双-苯并咪唑基喹喔啉信号的几种形式之间的自缔合，质子交换，构象和/或互变异构交换，且NMR光谱中的苯并咪唑片段变宽。苯并咪唑片段与分子的喹喔啉核心之间的共轭作用比喹喔啉衍生物（10c）与其噻二唑[ f ]-（17）和吡咯并[ a ]-（19）环化了衍生物，导致整个分子的平面度更大。
• B(C ₆ F ₅ ) ₃ ‐Catalyzed Deoxygenative Reduction of Amides to Amines with Ammonia Borane
  作者：Yixiao Pan、Zhenli Luo、Jiahong Han、Xin Xu、Changjun Chen、Haoqiang Zhao、Lijin Xu、Qinghua Fan、Jianliang Xiao

  DOI：10.1002/adsc.201801447

  日期：2019.5.14

  The first B(C6F5)3‐catalyzed deoxygenative reduction of amides into the corresponding amines with readily accessible and stable ammonia borane (AB) as a reducing agent under mild reaction conditions is reported. This metal‐free protocol provides facile access to a wide range of structurally diverse amine products in good to excellent yields, and various functional groups including those that are reduction‐sensitive

  据报道，在温和的反应条件下，用易于获得且稳定的氨硼烷（AB）作为还原剂，将酰胺进行的首次B（C 6 F 5）3催化脱氧还原为相应的胺。该无金属方案可轻松获得各种结构多样的胺产品，且收率高至优异，并且对各种官能团（包括对还原敏感的官能团）均具有良好的耐受性。该新方法也适用于手性酰胺底物，而不会破坏对映体的纯度。BF 3  OEt 2助催化剂在该反应中的作用是通过酰胺-硼加合物的原位形成来活化酰胺羰基。
• Fragment Based Design of New H₄ Receptor−Ligands with Anti-inflammatory Properties in Vivo
  作者：Rogier A. Smits、Herman D. Lim、Agnes Hanzer、Obbe P. Zuiderveld、Elena Guaita、Maristella Adami、Gabriella Coruzzi、Rob Leurs、Iwan J. P. de Esch

  DOI：10.1021/jm7014217

  日期：2008.4.1

  and evaluated a series of compounds at the human histamine H 4 receptor (H 4R) from which 2-(4-methyl-piperazin-1-yl)-quinoxaline ( 3) was identified as a new lead structure for H 4R ligands. Exploration of the structure-activity relationship (SAR) of this scaffold led to the identification of 6,7-dichloro 3-(4-methylpiperazin-1-yl)quinoxalin-2(1 H)-one (VUF 10214, 57) and 2-benzyl-3-(4-methyl-pip

  使用先前报告的灵活比对模型，我们已经设计，合成和评估了人类组胺H 4受体（H 4R）上的一系列化合物，其中2-（4-甲基-哌嗪-1-基）-喹喔啉（3）被鉴定为H 4R配体的新的先导结构。探索该支架的构效关系（SAR）导致鉴定出6,7-二氯3-（4-甲基哌嗪-1-基）喹喔啉-2（1 H）-一（VUF 10214，57）和2-苄基-3-（4-甲基-哌嗪-1-基）喹喔啉（VUF 10148，20）作为具有纳摩尔亲和力的强效H 4R配体。在大鼠体内的研究表明，化合物57在角叉菜胶诱导的爪水肿模型中具有显着的抗炎特性。
• Choline Chloride-based Eutectic Mixtures for Greener Synthesis of Quinoxaline-2,3-diol Derivatives and Terephthalaldehyde bis-(2-Aminophenylimine)
  作者：Kioumars Aghapoor、Farshid Mohsenzadeh、Hossein Reza Darabi、Hani Sayahi

  DOI：10.1080/00304948.2021.2010467

  日期：2022.3.4

  (2022). Choline Chloride-based Eutectic Mixtures for Greener Synthesis of Quinoxaline-2,3-diol Derivatives and Terephthalaldehyde bis-(2-Aminophenylimine) Organic Preparations and Procedures International: Vol. 54, No. 2, pp. 157-166.

  （2022 年）。基于氯化胆碱的低共熔混合物，用于更环保地合成喹喔啉-2,3-二醇衍生物和对苯二甲醛双-(2-氨基苯亚胺)有机制剂和程序国际：卷。54，第 2 期，第 157-166 页。
• HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE
  申请人：Borchardt Allen J.

  公开号：US20100120741A1

  公开（公告）日：2010-05-13

  The present invention relates to compounds and methods which may be useful as inhibitors of H 1 R and/or H 4 R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

  本发明涉及化合物和方法，这些化合物和方法可能用作H1R和/或H4R的抑制剂，用于治疗或预防炎症性、自身免疫性、过敏性和眼部疾病。